SLC25A10 performs an oncogenic role in human osteosarcoma

Wang,Gaoyuan; Xia,Jianjun; Chen,Cheng; Qiu,Jie; Sun,Po; Peng,Zhiwei; Chen,Xiaoyu; Xu,Bin

doi:10.3892/ol.2020.11863

SLC25A10 performs an oncogenic role in human osteosarcoma

Authors:
- Gaoyuan Wang
- Jianjun Xia
- Cheng Chen
- Jie Qiu
- Po Sun
- Zhiwei Peng
- Xiaoyu Chen
- Bin Xu
View Affiliations

Affiliations: Department of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China, Department of Orthopaedics, East District of The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 231600, P.R. China, Department of Orthopaedics, People's Hospital of Fuyang City, Fuyang, Anhui 236015, P.R. China, Department of Histology and Embryology, Anhui Medical University, Hefei, Anhui 230023, P.R. China
Published online on: July 14, 2020 https://doi.org/10.3892/ol.2020.11863
Article Number: 2
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is one of the most common primary malignant bone tumors in adolescents. It is associated with high risk of relapse and the outcomes of patients with high‑grade osteosarcoma remain poor. Therefore, additional studies investigating the molecular mechanisms involved in tumor initiation, growth, migration and invasion of osteosarcoma are necessary. In the present study, the protein levels of solute carrier family 25 member 10 (SLC25A10) were increased in osteosarcoma tissue, compared with normal bone tissue. In patients with osteosarcoma, high expression levels of SLC25A10 were associated with poor clinicopathological parameters, including metastasis, clinical Enneking stage, relapse‑free survival and overall survival rates. Short hairpin RNA knockdown of SLC25A10 significantly suppressed cell proliferation as determined by cell counting, MTT assay and cell colony formation assays. In addition, SLC25A10 knockdown caused an increase in apoptosis and a decrease in mitosis in osteosarcoma cells. Cyclin E1 (CCNE1) was positively regulated by SLC25A10, while P21 and P27 were negatively regulated by SLC25A10. Therefore, SLC25A10 may play an oncogenic role in human osteosarcoma, which could be mediated by CCNE1, P21 and P27.

View Figures

View References

1	Fuja DG, Rainusso NC, Shuck RL, Kurenbekova L, Donehower LA and Yustein JT: Transglutaminase-2 promotes metastatic and stem-like phenotypes in osteosarcoma. Am J Cancer Res. 8:1752–1763. 2018.PubMed/NCBI
2	Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, González MV, Baldini N, Garcia-Castro J and Rodriguez R: Osteosarcoma: Cells-of-Origin, cancer stem cells, and targeted therapies. Stem Cells Int. 2016:36317642016. View Article : Google Scholar : PubMed/NCBI
3	Zhao X, Sun S, Xu J, Luo Y, Xin Y and Wang Y: MicroRNA-152 inhibits cell proliferation of osteosarcoma by directly targeting Wnt/β-catenin signaling pathway in a DKK1-dependent manner. Oncol Rep. 40:767–774. 2018.PubMed/NCBI
4	He R, Wu JX, Zhang Y, Chen H and Yang L: LncRNA LINC00628 overexpression inhibits the growth and invasion through regulating PI3K/Akt signaling pathway in osteosarcoma. Eur Rev Med Pharmaco Sci. 22:5857–5866. 2018.
5	Nie WB, Zhao LM, Guo R, Wang MX and Ye FG: Circular RNA circ-NT5C2 acts as a potential novel biomarker for prognosis of osteosarcoma. Eur Rev Med Pharmaco Sci. 22:6239–6244. 2018.
6	Zuo DQ, Shogren KL, Zang J, Jewison DE, Waletzki BE, Miller AL II, Okuno SH, Cai Z, Yaszemski MJ and Maran A: Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells. J Exp Clin Canc Res. 37:2442018. View Article : Google Scholar
7	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
8	Tabak SA, Khalifa SE and Fathy Y: HER-2 Immunohistochemical Expression in Bone Sarcomas: A New hope for patients with osteosarcoma. Open Access Maced J Med Sci. 6:1555–1560. 2018. View Article : Google Scholar : PubMed/NCBI
9	Meazza C and Scanagatta P: Metastatic osteosarcoma: A challenging multidisciplinary treatment. Expert Rev Anticancer Ther. 16:543–556. 2016. View Article : Google Scholar : PubMed/NCBI
10	Zhou XS, Paredes JA, Krishnan S, Curbo S and Karlsson A: The mitochondrial carrier SLC25A10 regulates cancer cell growth. Oncotarget. 6:9271–9283. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhao Q, Zhou XS, Curbo S and Karlsson A: Metformin downregulates the mitochondrial carrier SLC25A10 in a glucose dependent manner. Biochem Pharmacol. 156:444–450. 2018. View Article : Google Scholar : PubMed/NCBI
12	Mizuarai S, Miki S, Araki H, Takahashi K and Kotani H: Identification of dicarboxylate carrier Slc25a10 as malate transporter in de novo fatty acid synthesis. J Biol Chem. 280:32434–32441. 2005. View Article : Google Scholar : PubMed/NCBI
13	Hlouschek J, Ritter V, Wirsdorfer F, Klein D, Jendrossek V and Matschke J: Targeting SLC25A10 alleviates improved antioxidant capacity and associated radioresistance of cancer cells induced by chronic-cycling hypoxia. Cancer Lett. 439:24–38. 2018. View Article : Google Scholar : PubMed/NCBI
14	Kulyte A, Ehrlund A, Arner P and Dahlman I: Global transcriptome profiling identifies KLF15 and SLC25A10 as modifiers of adipocytes insulin sensitivity in obese women. PLoS One. 12:e01784852017. View Article : Google Scholar : PubMed/NCBI
15	Huypens P, Pillai R, Sheinin T, Schaefer S, Huang M, Odegaard ML, Ronnebaum SM, Wettig SD and Joseph JW: The dicarboxylate carrier plays a role in mitochondrial malate transport and in the regulation of glucose-stimulated insulin secretion from rat pancreatic beta cells. Diabetologia. 54:135–145. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP, Rajala MW, Du X, Rollman B, Li W, et al: The hyperglycemia-induced inflammatory response in adipocytes: The role of reactive oxygen species. J Biol Chem. 280:4617–4626. 2005. View Article : Google Scholar : PubMed/NCBI
17	Lockwood WW, Stack D, Morris T, Grehan D, O'Keane C, Stewart GL, Cumiskey J, Lam WL, Squire JA, Thomas DM and O'Sullivan MJ: Cyclin E1 is amplified and overexpressed in osteosarcoma. J Mol Diagn. 13:289–296. 2011. View Article : Google Scholar : PubMed/NCBI
18	Zhao ZM, Yost SE, Hutchinson KE, Li SM, Yuan YC, Noorbakhsh J, Liu Z, Warden C, Johnson RM, Wu X, et al: CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer. BMC Cancer. 19:962019. View Article : Google Scholar : PubMed/NCBI
19	Sang Y, Zhang R, Sun L, Chen KK, Li SW, Xiong L, Peng Y, Zeng L and Huang G: MORF4L1 suppresses cell proliferation, migration and invasion by increasing p21 and E-cadherin expression in nasopharyngeal carcinoma. Oncol Lett. 17:294–302. 2019.PubMed/NCBI
20	Guo Q, Xiong Y, Song Y, Hua K and Gao S: ARHGAP17 suppresses tumor progression and up-regulates P21 and P27 expression via inhibiting PI3K/AKT signaling pathway in cervical cancer. Gene. 692:9–16. 2019. View Article : Google Scholar : PubMed/NCBI
21	Li Z, Tao Y, Wang X, Jiang P, Li J, Peng M, Zhang X, Chen K, Liu H, Zhen P, et al: Tumor-secreted exosomal miR-222 promotes tumor progression via regulating P27 Expression and Re-localization in pancreatic cancer. Cell Physiol Biochem. 51:610–629. 2018. View Article : Google Scholar : PubMed/NCBI
22	Chen CY, Lei J, Zheng Q, Tan S, Ding KS and Yu CJ: Poly(rC) binding protein 2 (PCBP2) promotes the viability of human gastric cancer cells by regulating CDK2. FEBS Open Bio. 8:764–773. 2018. View Article : Google Scholar : PubMed/NCBI
23	Chen C, Zheng Q, Kang W and Yu C: Long non-coding RNA LINC00472 suppresses hepatocellular carcinoma cell proliferation, migration and invasion through miR-93-5p/PDCD4 pathway. Clin Res Hepatol Gastroenterol. 43:436–445. 2018. View Article : Google Scholar : PubMed/NCBI
24	Wu X, Cai ZD, Lou LM and Zhu YB: Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients. Cancer Epidemiol. 36:212–216. 2012. View Article : Google Scholar : PubMed/NCBI
25	Cao W, Fang L, Teng S, Chen H and Liu T: MicroRNA-466 inhibits osteosarcoma cell proliferation and induces apoptosis by targeting CCND1. Exp Ther Med. 16:5117–5122. 2018.PubMed/NCBI
26	Wang J, Xu G, Shen F and Kang Y: miR-132 targeting cyclin E1 suppresses cell proliferation in osteosarcoma cells. Tumour Biol. 35:4859–4865. 2014. View Article : Google Scholar : PubMed/NCBI
27	Liu Q, Geng P, Shi L, Wang Q and Wang P: miR-29 promotes osteosarcoma cell proliferation and migration by targeting PTEN. Oncol Lett. 17:883–890. 2019.PubMed/NCBI
28	Zhao R, He H, Zhu Y, Wan J, Li Y, Gao S and Zhang C: MiR-204/14-3-3ζ axis regulates osteosarcoma cell proliferation through SATA3 pathway. Pharmazie. 72:593–598. 2017.PubMed/NCBI
29	Wang J, Wang G, Li B, Qiu C and He M: miR-141-3p is a key negative regulator of the EGFR pathway in osteosarcoma. Onco Targets Ther. 11:4461–4478. 2018. View Article : Google Scholar : PubMed/NCBI
30	Lv H, Gao G, Zhang L and Sun Y: Polo-like kinase 3 inhibits osteosarcoma cell proliferation and tumorigenesis via cooperative interaction with p21. Mol Med Rep. 12:6789–6796. 2015. View Article : Google Scholar : PubMed/NCBI
31	Zhang F and Peng H: LncRNA-ANCR regulates the cell growth of osteosarcoma by interacting with EZH2 and affecting the expression of p21 and p27. J Orthop Surg Res. 12:1032017. View Article : Google Scholar : PubMed/NCBI
32	Ghosh T, Varshney A, Kumar P, Kaur M, Kumar V, Shekhar R, Devi R, Priyanka P, Khan MM and Saxena S: MicroRNA-874-mediated inhibition of the major G₁/S phase cyclin, CCNE1, is lost in osteosarcomas. J Biol Chem. 292:21264–21281. 2017. View Article : Google Scholar : PubMed/NCBI
33	Shukla K, Sharma AK, Ward A, Will R, Hielscher T, Balwierz A, Breunig C, Münstermann E, König R, Keklikoglou I and Wiemann S: MicroRNA-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. Mol Oncol. 9:1106–1119. 2015. View Article : Google Scholar : PubMed/NCBI
34	Yao Y, Luo J, Sun Q, Xu T, Sun S, Chen M, Lin X, Qian Q, Zhang Y, Cao L, et al: HOXC13 promotes proliferation of lung adenocarcinoma via modulation of CCND1 and CCNE1. Am J Cancer Res. 7:1820–1834. 2017.PubMed/NCBI
35	Zhang Y, Peng Z, Zhao YS and Chen L: microRNA-25 inhibits cell apoptosis of human gastric adenocarcinoma cell line AGS via regulating CCNE1 and MYC. Med Sci Monitor. 22:1415–1420. 2016. View Article : Google Scholar
36	Zhang X, Hu SJ, Zhang X, Wang L, Zhang X, Yan B, Zhao J, Yang A and Zhang R: MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 443:1078–1084. 2014. View Article : Google Scholar : PubMed/NCBI
37	Fujii R, Osaka E, Sato K and Tokuhashi Y: MiR-1 suppresses proliferation of osteosarcoma cells by Up-regulating p21 via PAX3. Cancer Genom Proteom. 16:71–79. 2019. View Article : Google Scholar
38	Huang J, Deng GR, Liu TM, Chen WZ and Zhou Y: Long noncoding RNA PCAT-1 acts as an oncogene in osteosarcoma by reducing p21 levels. Biochem Biophys Res Commun. 495:2622–2629. 2018. View Article : Google Scholar : PubMed/NCBI
39	Ding Y, Wang YC, Chen J, Hu Y, Cao Z, Ren P and Zhang Y: p21 overexpression sensitizes osteosarcoma U2OS cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade. Tumor Biol. 35:3119–3123. 2014. View Article : Google Scholar
40	Li Z, Yu D, Li H, Lv Y and Li S: Long noncoding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. Int J Oncol. 54:1033–1042. 2019.PubMed/NCBI
41	Guo L, Gu J, Hou S, Liu D, Zhou M, Hua T, Zhang J, Ge Z and Xu J: Long non-coding RNA DANCR promotes the progression of non-small-cell lung cancer by inhibiting p21 expression. Onco Targets Ther. 12:135–146. 2019. View Article : Google Scholar : PubMed/NCBI
42	Liao QD, Zhong D and Chen Q: Protein expression of Skp2 in osteosarcoma and its relation with prognosis. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 33:606–611. 2008.(In Chinese). PubMed/NCBI
43	Hu XH, Zhao ZX, Dai J, Geng DC and Xu YZ: MicroRNA-221 regulates osteosarcoma cell proliferation, apoptosis, migration, and invasion by targeting CDKN1B/p27. J Cell Biochem. 120:4665–4674. 2019. View Article : Google Scholar : PubMed/NCBI
44	Li H, Guan H, Guo Y, Liang W, Liu L, He X, Ke W, Cao X, Xiao H and Li Y: CITED1 promotes proliferation of papillary thyroid cancer cells via the regulation of p21 and p27. Cell Biosci. 8:572018. View Article : Google Scholar : PubMed/NCBI
45	Vijay K, Sowmya PR, Arathi BP, Shilpa S, Shwetha HJ, Raju M, Baskaran V and Lakshminarayana R: Low-dose doxorubicin with carotenoids selectively alters redox status and upregulates oxidative stress-mediated apoptosis in breast cancer cells. Food Chem Toxicol. 118:675–690. 2018. View Article : Google Scholar : PubMed/NCBI
46	Zhang D, Wang Y, Liang Y, Zhang M, Wei J, Zheng X, Li F, Meng Y, Zhu NW, Li J, et al: Loss of p27 upregulates MnSOD in a STAT3-dependent manner, disrupts intracellular redox activity and enhances cell migration. J Cell Sci. 127:2920–2933. 2014. View Article : Google Scholar : PubMed/NCBI
47	Tang Z, Fang Y and Du R: MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer. Biochem Biophys Res Commun. 512:331–337. 2019. View Article : Google Scholar : PubMed/NCBI
48	Yang M, Peng Y, Liu W, Zhou M, Meng Q and Yuan C: Sirtuin 2 expression suppresses oxidative stress and senescence of nucleus pulposus cells through inhibition of the p53/p21 pathway. Biochem Biophys Res Commun. 513:616–622. 2019. View Article : Google Scholar : PubMed/NCBI